WO2007013896A2 - Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors - Google Patents
Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors Download PDFInfo
- Publication number
- WO2007013896A2 WO2007013896A2 PCT/US2006/018726 US2006018726W WO2007013896A2 WO 2007013896 A2 WO2007013896 A2 WO 2007013896A2 US 2006018726 W US2006018726 W US 2006018726W WO 2007013896 A2 WO2007013896 A2 WO 2007013896A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- nhr
- group
- lower alkyl
- fluoro
- Prior art date
Links
- 0 C*C*N1N=*C(**)C1* Chemical compound C*C*N1N=*C(**)C1* 0.000 description 10
- WGSDEVIRNPPEQV-UHFFFAOYSA-N O=Cc(c1c2nccc1)c[n]2S(c1ccccc1)(=O)=O Chemical compound O=Cc(c1c2nccc1)c[n]2S(c1ccccc1)(=O)=O WGSDEVIRNPPEQV-UHFFFAOYSA-N 0.000 description 1
- CTHZFVULRMIHJC-UHFFFAOYSA-N P[n]1c2ncccc2cc1 Chemical compound P[n]1c2ncccc2cc1 CTHZFVULRMIHJC-UHFFFAOYSA-N 0.000 description 1
- CHQXUUFDRORIGN-UHFFFAOYSA-N Sc1c[nH]c2ncccc12 Chemical compound Sc1c[nH]c2ncccc12 CHQXUUFDRORIGN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0610066-0A BRPI0610066A2 (pt) | 2005-05-17 | 2006-05-16 | compostos que modulam atividade de c-kit e c-fms e usos para estes |
NZ563444A NZ563444A (en) | 2005-05-17 | 2006-05-16 | Pyrrolo(2,3-b)pyridine derivatives as protein kinase inhibitors |
AU2006272951A AU2006272951A1 (en) | 2005-05-17 | 2006-05-16 | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
JP2008512402A JP2008545652A (ja) | 2005-05-17 | 2006-05-16 | c−kitおよびc−fms活性を調節する化合物およびその用途 |
MX2007014377A MX2007014377A (es) | 2005-05-17 | 2006-05-16 | Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina. |
CA002608733A CA2608733A1 (en) | 2005-05-17 | 2006-05-16 | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
EP06813186A EP1885723A2 (en) | 2005-05-17 | 2006-05-16 | Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors |
IL187344A IL187344A0 (en) | 2005-05-17 | 2007-11-13 | Compounds modulating c-kit and c-fms activity and uses therefor |
NO20075992A NO20075992L (no) | 2005-05-17 | 2007-11-23 | Forbindelser som modulerer C-Kit og C-FMS aktivitet og anvendelser derav |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68205105P | 2005-05-17 | 2005-05-17 | |
US68206305P | 2005-05-17 | 2005-05-17 | |
US68204205P | 2005-05-17 | 2005-05-17 | |
US60/682,063 | 2005-05-17 | ||
US60/682,042 | 2005-05-17 | ||
US60/682,051 | 2005-05-17 | ||
US69296005P | 2005-06-22 | 2005-06-22 | |
US69275005P | 2005-06-22 | 2005-06-22 | |
US60/692,960 | 2005-06-22 | ||
US60/692,750 | 2005-06-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007013896A2 true WO2007013896A2 (en) | 2007-02-01 |
WO2007013896A3 WO2007013896A3 (en) | 2007-05-31 |
Family
ID=37683773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/018726 WO2007013896A2 (en) | 2005-05-17 | 2006-05-16 | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
Country Status (14)
Cited By (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008064265A2 (en) * | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
WO2008080001A2 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
JP2009523812A (ja) * | 2006-01-19 | 2009-06-25 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 融合へテロ二環式キナーゼ阻害剤 |
WO2009111280A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
WO2009143018A2 (en) * | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009143024A2 (en) * | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009152087A1 (en) * | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor |
WO2010111527A1 (en) * | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
WO2011025968A1 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase |
EP2313411A1 (en) * | 2008-06-10 | 2011-04-27 | Plexxikon, Inc. | 5h-pyrr0l0 [2,3-b]pyrazine derivatives for kinase modulation, and indications therefor |
US8173635B2 (en) | 2007-11-02 | 2012-05-08 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
US8338452B2 (en) | 2008-02-29 | 2012-12-25 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
EP2560972A2 (en) * | 2010-04-21 | 2013-02-27 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8394795B2 (en) | 2008-02-29 | 2013-03-12 | Array Biopharma Inc. | Pyrazole [3, 4-B] pyridine Raf inhibitors |
US8580803B2 (en) | 2009-12-30 | 2013-11-12 | Arqule, Inc. | Substituted pyrrolo-aminopyrimidine compounds |
US8648086B2 (en) | 2009-08-24 | 2014-02-11 | Ascepion Pharmaceuticals, Inc. | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors |
US8741920B2 (en) | 2009-08-03 | 2014-06-03 | Hoffmann-La Roche, Inc. | Process for the manufacture of pharmaceutically active compounds |
WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
US9163021B2 (en) | 2012-10-04 | 2015-10-20 | Pfizer Limited | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9440969B2 (en) | 2009-12-23 | 2016-09-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9550768B2 (en) | 2011-05-17 | 2017-01-24 | Plexxikon Inc. | Kinase modulation and indications therefor |
EP3124472A1 (en) | 2011-12-31 | 2017-02-01 | BeiGene, Ltd. | Fused tricyclic compounds as raf kinase inhibitors |
US9617267B2 (en) | 2009-11-18 | 2017-04-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9624213B2 (en) | 2011-02-07 | 2017-04-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US9663517B2 (en) | 2009-04-03 | 2017-05-30 | Plexxikon Inc. | Compositions and uses thereof |
US9676748B2 (en) | 2012-12-21 | 2017-06-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9695169B2 (en) | 2012-05-31 | 2017-07-04 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
US9718847B2 (en) | 2013-03-15 | 2017-08-01 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9771369B2 (en) | 2014-03-04 | 2017-09-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9771363B2 (en) | 2015-09-21 | 2017-09-26 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9822109B2 (en) | 2013-03-15 | 2017-11-21 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9844539B2 (en) | 2007-07-17 | 2017-12-19 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9856259B2 (en) | 2014-09-15 | 2018-01-02 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9873700B2 (en) | 2013-05-30 | 2018-01-23 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
US9938273B2 (en) | 2015-12-07 | 2018-04-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10160747B2 (en) | 2016-03-16 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10227357B2 (en) | 2012-09-06 | 2019-03-12 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
US10435404B2 (en) | 2017-07-25 | 2019-10-08 | Plexxikon Inc. | Formulations of a compound modulating kinases |
EP3550031A1 (en) | 2012-07-24 | 2019-10-09 | Pharmacyclics, LLC | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
US10508085B2 (en) | 2016-09-22 | 2019-12-17 | Plexxikon Inc. | Compounds and methods for IDO and TDO modulation, and indications therefor |
US10577366B2 (en) | 2017-03-20 | 2020-03-03 | Plexxikon Inc. | Crystalline forms of a compound that inhibits bromodomain |
WO2020079581A1 (en) | 2018-10-16 | 2020-04-23 | Novartis Ag | Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy |
US10703757B2 (en) | 2016-12-23 | 2020-07-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
US10717735B2 (en) | 2017-10-13 | 2020-07-21 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US11020398B2 (en) | 2016-08-24 | 2021-06-01 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
WO2021144360A1 (en) | 2020-01-17 | 2021-07-22 | F. Hoffmann-La Roche Ag | Small molecule csf-1r inhibitors in therapeutic and cosmetic uses |
US11103505B2 (en) | 2017-10-27 | 2021-08-31 | Plexxikon Inc. | Formulations of a compound modulating kinases |
US11149011B2 (en) | 2018-03-20 | 2021-10-19 | Plexxikon Inc. | Compounds and methods for IDO and TDO modulation, and indications therefor |
US11274108B2 (en) | 2015-07-20 | 2022-03-15 | Genzyme Corporation | Colony stimulating factor-1 receptor (CSF-1R) inhibitors |
WO2022195551A1 (en) | 2021-03-18 | 2022-09-22 | Novartis Ag | Biomarkers for cancer and methods of use thereof |
US11530216B2 (en) | 2020-12-23 | 2022-12-20 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors |
US11731968B2 (en) | 2018-06-21 | 2023-08-22 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
US11858927B2 (en) | 2018-01-31 | 2024-01-02 | Heparegenix Gmbh | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
US11912701B2 (en) | 2018-07-16 | 2024-02-27 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2550361C (en) | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Compounds and methods for development of ret modulators |
US7498342B2 (en) * | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
EP1797881B1 (en) | 2004-09-17 | 2009-04-15 | Eisai R&D Management Co., Ltd. | Medicinal composition with improved stability and reduced gelation properties |
MX2007014377A (es) * | 2005-05-17 | 2008-02-06 | Plexxikon Inc | Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina. |
BRPI0611863B1 (pt) * | 2005-06-22 | 2021-11-23 | Plexxikon, Inc | Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo |
EP2281901B1 (en) | 2005-08-02 | 2013-11-27 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
JP5209966B2 (ja) * | 2005-09-01 | 2013-06-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 崩壊性の改善された医薬組成物の製造方法 |
MX2008014450A (es) * | 2006-05-18 | 2009-03-09 | Mannkind Corp | Inhibidores de cinasa intracelular. |
EP2036557B1 (en) | 2006-05-18 | 2015-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
PE20121126A1 (es) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
CA2716947A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
JP2012509342A (ja) * | 2008-11-20 | 2012-04-19 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換ピロロ[2,3−b]−ピリジンおよび−ピラジン |
BRPI0922937A2 (pt) * | 2008-12-05 | 2019-09-24 | Hoffmann La Roche | inibidores de pirrolopirazinil uréia quinase |
BR112012012156A2 (pt) * | 2009-11-06 | 2015-09-08 | Plexxikon Inc | compostos e métodos para modulação de cinase, e indicações para esta |
AU2010333752B2 (en) * | 2009-12-21 | 2014-12-04 | Array Biopharma Inc. | Substituted N-(1H-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cFMS inhibitors |
US20130072495A1 (en) | 2010-05-14 | 2013-03-21 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
AR081039A1 (es) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | Inhibidores biciclicos fusionados de quinasa |
AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
UA108926C2 (ru) * | 2011-04-05 | 2015-06-25 | Пфайзер Лімітед | LibreOffice? [2,3-D] +" +" !+ |
WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
US20140088114A1 (en) | 2011-05-16 | 2014-03-27 | OSI Pharmaceuticals ,LLC | Fused bicyclic kinase inhibitors |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
BR112015009004A8 (pt) | 2012-12-21 | 2021-07-20 | Eisai R&D Man Co Ltd | forma amorfa de derivado de quinolina e método de produção da mesma |
MX368099B (es) | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. |
WO2016004272A1 (en) | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
HRP20221047T1 (hr) | 2014-08-28 | 2022-11-11 | Eisai R&D Management Co., Ltd. | Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju |
CN107427505A (zh) | 2015-02-25 | 2017-12-01 | 卫材R&D管理有限公司 | 用于抑制喹啉衍生物的苦味的方法 |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
US9802932B2 (en) | 2015-05-06 | 2017-10-31 | Plexxikon Inc. | Solid forms of a compound modulating kinases |
HUE047657T2 (hu) | 2015-05-06 | 2020-05-28 | Plexxikon Inc | Kináz-moduláló hatású 1H-pirrolo[2,3-b]piridin származékok szintézise |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
CN109715631B (zh) * | 2016-09-16 | 2022-02-18 | 德国亥姆霍兹慕尼黑中心健康与环境研究中心(有限公司) | Traf 6抑制剂 |
WO2018233527A1 (zh) * | 2017-06-19 | 2018-12-27 | 上海和誉生物医药科技有限公司 | 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用 |
EP3953351A1 (en) | 2019-04-09 | 2022-02-16 | Plexxikon Inc. | Condensed azines for ep300 or cbp modulation and indications therefor |
EP4139296A1 (en) | 2020-04-23 | 2023-03-01 | Opna Immuno Oncology, SA | Compounds and methods for cd73 modulation and indications therefor |
WO2022040512A1 (en) | 2020-08-21 | 2022-02-24 | Plexxikon Inc. | Combinational drug anticancer therapies |
CN115557985B (zh) * | 2022-12-06 | 2023-03-10 | 成都泰蓉生物科技有限公司 | 一种选择性裂解硫醚中c-s键合成硅烷的方法 |
Citations (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
US5434049A (en) | 1992-02-28 | 1995-07-18 | Hitachi, Ltd. | Separation of polynucleotides using supports having a plurality of electrode-containing cells |
US5449614A (en) | 1988-09-01 | 1995-09-12 | Whitehead Institue For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
US5474935A (en) | 1990-05-23 | 1995-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus (AAV)-based eucaryotic vectors |
WO1996017958A1 (en) | 1994-12-09 | 1996-06-13 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
WO1996018738A2 (en) | 1994-12-15 | 1996-06-20 | Sugen, Inc. | PROBIN TYROSINE KINASE (PYK2) ITS cDNA CLONING AND ITS USES |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5580859A (en) | 1989-03-21 | 1996-12-03 | Vical Incorporated | Delivery of exogenous DNA sequences in a mammal |
US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
US5632957A (en) | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
US5658775A (en) | 1988-05-17 | 1997-08-19 | Sloan-Kettering Institute For Cancer Research | Double copy retroviral vector |
WO1997046313A1 (en) | 1996-06-07 | 1997-12-11 | Eos Biotechnology, Inc. | Immobilised linear oligonucleotide arrays |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US5721118A (en) | 1995-10-31 | 1998-02-24 | The Regents Of The University Of California, San Diego | Mammalian artificial chromosomes and methods of using same |
US5744305A (en) | 1989-06-07 | 1998-04-28 | Affymetrix, Inc. | Arrays of materials attached to a substrate |
US5770456A (en) | 1989-06-07 | 1998-06-23 | Affymetrix, Inc. | Cyclic nucleic acid and polypeptide arrays |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
WO1999009217A1 (en) | 1997-08-15 | 1999-02-25 | Hyseq, Inc. | Methods and compositions for detection or quantification of nucleic acid species |
US5959098A (en) | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
US5965452A (en) | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
WO1999051773A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
US6013440A (en) | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US6048695A (en) | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
US6096718A (en) | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
US6107478A (en) | 1995-09-08 | 2000-08-22 | Pedersen; Finn Skou | Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector |
US6110458A (en) | 1991-07-26 | 2000-08-29 | University Of Rochester | Cancer therapy utilizing ex vivo gene transduction |
US6110456A (en) | 1995-06-07 | 2000-08-29 | Yale University | Oral delivery or adeno-associated viral vectors |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
US6117681A (en) | 1995-03-29 | 2000-09-12 | Bavarian Nordic Research Inst. A/S | Pseudotyped retroviral particles |
US20010008765A1 (en) | 1999-12-06 | 2001-07-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
US20010012537A1 (en) | 1999-07-30 | 2001-08-09 | Anderson Norman G. | Dry deposition of materials for microarrays using matrix displacement |
US20010014449A1 (en) | 1993-11-01 | 2001-08-16 | Michael I. Nerenberg | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
US20010014448A1 (en) | 1997-09-30 | 2001-08-16 | Surmodics, Inc. | Target molecule attachment to surfaces |
US6277628B1 (en) | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
US6277489B1 (en) | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
US20010016322A1 (en) | 1999-04-27 | 2001-08-23 | Caren Michael P. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
US20010018642A1 (en) | 1997-07-25 | 2001-08-30 | David Balaban | Method and system for providing a probe array chip design database |
US20010019827A1 (en) | 1997-09-11 | 2001-09-06 | Dawson Elliott P. | Method of making high density arrays |
US20040002534A1 (en) | 1999-12-22 | 2004-01-01 | Sugen, Inc. | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
WO2004016610A1 (en) | 2002-08-14 | 2004-02-26 | Astrazeneca Ab | Substituted pyrrolopyridines |
US20040077595A1 (en) | 2002-09-06 | 2004-04-22 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US617687A (en) * | 1899-01-10 | Vapor-burning apparatus | ||
US2234705A (en) * | 1940-04-12 | 1941-03-11 | Eastman Kodak Co | Cellulose organic derivative composition containing esters of monoalkoxy benzoic acids |
US2413258A (en) * | 1942-07-07 | 1946-12-24 | United Gas Improvement Co | Polystyrene-type resins plasticized with high boiling fatty acid alkyl esters |
DE2413258A1 (de) | 1974-03-20 | 1975-10-02 | Bayer Ag | Alkoxycarbonylphenylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
GB1573212A (en) * | 1976-04-15 | 1980-08-20 | Technicon Instr | Immunoassay for gentamicin |
US4664504A (en) * | 1983-01-20 | 1987-05-12 | Tokyo Shibaura Denki Kabushiki Kaisha | Image forming apparatus |
US4568649A (en) * | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
US4626513A (en) * | 1983-11-10 | 1986-12-02 | Massachusetts General Hospital | Method and apparatus for ligand detection |
ATE56096T1 (de) | 1984-03-15 | 1990-09-15 | Immunex Corp | Test zur sofortigen feststellung von liganden, testsatz und seine herstellung. |
US5688655A (en) * | 1988-02-10 | 1997-11-18 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
DE4022414A1 (de) | 1990-07-13 | 1992-01-16 | Bayer Ag | Substituierte pyrrolo-pyridine |
FR2687402B1 (fr) * | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
GB9226855D0 (en) * | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US5576319A (en) * | 1993-03-01 | 1996-11-19 | Merck, Sharp & Dohme Ltd. | Pyrrolo-pyridine derivatives |
ES2134929T3 (es) * | 1993-03-01 | 1999-10-16 | Merck Sharp & Dohme | Derivados de pirrolo-piridina como ligandos para receptores de dopamina. |
PL310443A1 (en) * | 1993-03-01 | 1995-12-11 | Merck Sharp & Dohme | Derivatives of pyrolo-pyridine |
US5840485A (en) * | 1993-05-27 | 1998-11-24 | Selectide Corporation | Topologically segregated, encoded solid phase libraries |
DE69434998T2 (de) * | 1993-05-27 | 2008-03-13 | Aventis Pharmaceuticals Inc. | Topologisch getrennte, kodierende Festphasen-Bibliotheken |
US5763198A (en) * | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
GB9416162D0 (en) | 1994-08-10 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
GB9416189D0 (en) | 1994-08-10 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
GB2298199A (en) * | 1995-02-21 | 1996-08-28 | Merck Sharp & Dohme | Synthesis of azaindoles |
GB9503400D0 (en) | 1995-02-21 | 1995-04-12 | Merck Sharp & Dohme | Therpeutic agents |
GB2299581A (en) | 1995-04-07 | 1996-10-09 | Merck Sharp & Dohme | 3-(Tetrahydropyridin-1-yl-methyl)pyrrolo[2,3-b]pyridine derivatives as ligands for dopamine receptor subtypes |
GB9507291D0 (en) * | 1995-04-07 | 1995-05-31 | Merck Sharp & Dohme | Therapeutic agents |
US5747276A (en) * | 1995-09-15 | 1998-05-05 | The Scripps Research Institute | Screening methods for the identification of novel antibiotics |
US5804585A (en) * | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
US6294330B1 (en) * | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
EP0972071A4 (en) * | 1997-03-07 | 2004-04-21 | Tropix Inc | TEST ARRANGEMENT FOR PROTEAS INHIBITORS |
US6235769B1 (en) * | 1997-07-03 | 2001-05-22 | Sugen, Inc. | Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase |
US6161776A (en) * | 1997-08-12 | 2000-12-19 | Nibco Inc. | Multi-layered, porous mat turf irrigation apparatus and method |
US6178384B1 (en) * | 1997-09-29 | 2001-01-23 | The Trustees Of Columbia University In The City Of New York | Method and apparatus for selecting a molecule based on conformational free energy |
AU4543899A (en) * | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
FR2793793B1 (fr) | 1999-05-19 | 2004-02-27 | Adir | Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CA2707827A1 (en) | 2001-04-11 | 2002-10-24 | Senju Pharmaceutical Co., Ltd. | Visual function disorder improving agents containing rho kinase inhibitors |
US6559169B2 (en) | 2001-04-24 | 2003-05-06 | Wyeth | Antidepressant azaheterocyclymethyl derivatives of 2,3-dihydro-1,4-benzodioxan |
GB0114417D0 (en) * | 2001-06-13 | 2001-08-08 | Boc Group Plc | Lubricating systems for regenerative vacuum pumps |
EP1267111A1 (en) | 2001-06-15 | 2002-12-18 | Dsm N.V. | Pressurized fluid conduit |
US20040171630A1 (en) | 2001-06-19 | 2004-09-02 | Yuntae Kim | Tyrosine kinase inhibitors |
US7291639B2 (en) | 2001-06-20 | 2007-11-06 | Wyeth | Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
UA75425C2 (en) | 2001-07-09 | 2006-04-17 | Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds | |
GB0117583D0 (en) | 2001-07-19 | 2001-09-12 | Astrazeneca Ab | Novel compounds |
US6858860B2 (en) * | 2001-07-24 | 2005-02-22 | Seiko Epson Corporation | Apparatus and method for measuring natural period of liquid |
GB0118479D0 (en) | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
JPWO2003037862A1 (ja) | 2001-10-30 | 2005-02-17 | 日本新薬株式会社 | アミド誘導体及び医薬 |
US20030236277A1 (en) | 2002-02-14 | 2003-12-25 | Kadow John F. | Indole, azaindole and related heterocyclic pyrrolidine derivatives |
US6884889B2 (en) | 2002-03-25 | 2005-04-26 | Bristol-Myers Squibb Co. | Processes for the preparation of antiviral 7-azaindole derivatives |
WO2003082869A1 (en) | 2002-03-28 | 2003-10-09 | Eisai Co., Ltd. | Azaindoles as inhibitors of c-jun n-terminal kinases |
JP2005534618A (ja) | 2002-03-28 | 2005-11-17 | エーザイ株式会社 | 神経変性疾患用の、c−junn−末端キナーゼ阻害剤としての7−アザインドール |
UA78999C2 (en) | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
TW200403243A (en) | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
US6878887B2 (en) * | 2002-08-07 | 2005-04-12 | Matsushita Electric Industrial Co., Ltd. | Anti-malfunction mechanism for variable output device |
CA2503905A1 (en) * | 2002-09-16 | 2004-03-25 | Plexxikon, Inc. | Crystal structure of pim-1 kinase |
US7696225B2 (en) * | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
SE0300119D0 (sv) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
SE0300120D0 (sv) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
US20050085463A1 (en) * | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
BRPI0407493A (pt) * | 2003-02-14 | 2006-02-14 | Wyeth Corp | derivados heterociclil-3-sulfinilazaindol ou -azaindazol como ligantes de 5-hidroxitriptamina-6 |
WO2004078923A2 (en) * | 2003-02-28 | 2004-09-16 | Plexxikon, Inc. | Pyk2 crystal structure and uses |
US20050164300A1 (en) * | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
DE10357510A1 (de) | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroarylsubstituierte Benzole |
CA2550361C (en) * | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Compounds and methods for development of ret modulators |
GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
GB0330042D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
GB0403635D0 (en) | 2004-02-18 | 2004-03-24 | Devgen Nv | Pyridinocarboxamides with improved activity as kinase inhibitors |
GB0405055D0 (en) | 2004-03-05 | 2004-04-07 | Eisai London Res Lab Ltd | JNK inhibitors |
EP2786995A1 (en) | 2004-03-30 | 2014-10-08 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
WO2005116035A1 (en) * | 2004-05-27 | 2005-12-08 | Pfizer Products Inc. | Pyrrolopyrimidine derivatives useful in cancer treatment |
AU2005265017A1 (en) * | 2004-06-17 | 2006-01-26 | Plexxikon, Inc. | Azaindoles modulating c-kit activity and uses therefor |
US7498342B2 (en) * | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
CA2572058A1 (en) | 2004-06-30 | 2006-01-12 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
BRPI0513916A (pt) | 2004-07-27 | 2008-05-20 | Sgx Pharmaceuticals Inc | moduladores de pirrol-piridina cinase |
AU2005269387A1 (en) * | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
US7709645B2 (en) * | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
US7361764B2 (en) * | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
US7626021B2 (en) * | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
JP5033119B2 (ja) | 2005-04-25 | 2012-09-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | キナーゼ阻害剤としての新規アザ複素環化合物 |
MX2007014377A (es) | 2005-05-17 | 2008-02-06 | Plexxikon Inc | Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina. |
EP1881983B1 (en) | 2005-05-20 | 2012-01-11 | Vertex Pharmaceuticals, Inc. | Pyrrolopyridines useful as inhibitors of protein kinase |
BRPI0611863B1 (pt) | 2005-06-22 | 2021-11-23 | Plexxikon, Inc | Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo |
GB0516156D0 (en) | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
PE20121126A1 (es) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
CL2008001540A1 (es) * | 2007-05-29 | 2009-05-22 | Sgx Pharmaceuticals Inc | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. |
-
2006
- 2006-05-16 MX MX2007014377A patent/MX2007014377A/es active IP Right Grant
- 2006-05-16 KR KR1020077029428A patent/KR20080027775A/ko not_active Application Discontinuation
- 2006-05-16 EP EP06813186A patent/EP1885723A2/en not_active Withdrawn
- 2006-05-16 NZ NZ563444A patent/NZ563444A/en not_active IP Right Cessation
- 2006-05-16 CA CA002608733A patent/CA2608733A1/en not_active Abandoned
- 2006-05-16 AU AU2006272951A patent/AU2006272951A1/en not_active Abandoned
- 2006-05-16 WO PCT/US2006/018726 patent/WO2007013896A2/en active Application Filing
- 2006-05-16 BR BRPI0610066-0A patent/BRPI0610066A2/pt not_active IP Right Cessation
- 2006-05-16 US US11/435,381 patent/US7846941B2/en active Active
- 2006-05-16 JP JP2008512402A patent/JP2008545652A/ja active Pending
-
2007
- 2007-11-13 IL IL187344A patent/IL187344A0/en unknown
- 2007-11-23 NO NO20075992A patent/NO20075992L/no not_active Application Discontinuation
- 2007-12-07 EC EC2007007985A patent/ECSP077985A/es unknown
- 2007-12-14 CR CR9591A patent/CR9591A/es not_active Application Discontinuation
-
2010
- 2010-12-01 US US12/958,376 patent/US20110166174A1/en not_active Abandoned
Patent Citations (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US5658775A (en) | 1988-05-17 | 1997-08-19 | Sloan-Kettering Institute For Cancer Research | Double copy retroviral vector |
US5449614A (en) | 1988-09-01 | 1995-09-12 | Whitehead Institue For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
US5580859A (en) | 1989-03-21 | 1996-12-03 | Vical Incorporated | Delivery of exogenous DNA sequences in a mammal |
US5770456A (en) | 1989-06-07 | 1998-06-23 | Affymetrix, Inc. | Cyclic nucleic acid and polypeptide arrays |
US6261776B1 (en) | 1989-06-07 | 2001-07-17 | Affymetrix, Inc. | Nucleic acid arrays |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5744305A (en) | 1989-06-07 | 1998-04-28 | Affymetrix, Inc. | Arrays of materials attached to a substrate |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5474935A (en) | 1990-05-23 | 1995-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus (AAV)-based eucaryotic vectors |
US6110458A (en) | 1991-07-26 | 2000-08-29 | University Of Rochester | Cancer therapy utilizing ex vivo gene transduction |
US5434049A (en) | 1992-02-28 | 1995-07-18 | Hitachi, Ltd. | Separation of polynucleotides using supports having a plurality of electrode-containing cells |
US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US20010014449A1 (en) | 1993-11-01 | 2001-08-16 | Michael I. Nerenberg | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
US5632957A (en) | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
WO1996017958A1 (en) | 1994-12-09 | 1996-06-13 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
WO1996018738A2 (en) | 1994-12-15 | 1996-06-20 | Sugen, Inc. | PROBIN TYROSINE KINASE (PYK2) ITS cDNA CLONING AND ITS USES |
US6117681A (en) | 1995-03-29 | 2000-09-12 | Bavarian Nordic Research Inst. A/S | Pseudotyped retroviral particles |
US6110456A (en) | 1995-06-07 | 2000-08-29 | Yale University | Oral delivery or adeno-associated viral vectors |
US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
US6107478A (en) | 1995-09-08 | 2000-08-22 | Pedersen; Finn Skou | Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector |
US5721118A (en) | 1995-10-31 | 1998-02-24 | The Regents Of The University Of California, San Diego | Mammalian artificial chromosomes and methods of using same |
US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
US6013440A (en) | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US5959098A (en) | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
WO1997046313A1 (en) | 1996-06-07 | 1997-12-11 | Eos Biotechnology, Inc. | Immobilised linear oligonucleotide arrays |
US5965452A (en) | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
US6258606B1 (en) | 1996-07-09 | 2001-07-10 | Nanogen, Inc. | Multiplexed active biologic array |
US6096718A (en) | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
US20010018642A1 (en) | 1997-07-25 | 2001-08-30 | David Balaban | Method and system for providing a probe array chip design database |
WO1999009217A1 (en) | 1997-08-15 | 1999-02-25 | Hyseq, Inc. | Methods and compositions for detection or quantification of nucleic acid species |
US20010019827A1 (en) | 1997-09-11 | 2001-09-06 | Dawson Elliott P. | Method of making high density arrays |
US20010014448A1 (en) | 1997-09-30 | 2001-08-16 | Surmodics, Inc. | Target molecule attachment to surfaces |
WO1999051773A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
US6048695A (en) | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
US6277628B1 (en) | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
US6277489B1 (en) | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
US20010016322A1 (en) | 1999-04-27 | 2001-08-23 | Caren Michael P. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
US20010012537A1 (en) | 1999-07-30 | 2001-08-09 | Anderson Norman G. | Dry deposition of materials for microarrays using matrix displacement |
US20010008765A1 (en) | 1999-12-06 | 2001-07-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
US20040002534A1 (en) | 1999-12-22 | 2004-01-01 | Sugen, Inc. | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
WO2004016610A1 (en) | 2002-08-14 | 2004-02-26 | Astrazeneca Ab | Substituted pyrrolopyridines |
US20040077595A1 (en) | 2002-09-06 | 2004-04-22 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
Non-Patent Citations (21)
Title |
---|
BOWTELL, NATURE GENETICS SUPP., vol. 21, 1999, pages 25 - 32 |
BUCHSCHER, J. VIROL., vol. 66, 1992, pages 2731 - 2739 |
CAPON, NATURE, vol. 377, 1989, pages 525 - 531 |
COLLIUOD, BIOCONJUGATE CHEM., vol. 4, 1993, pages 528 - 536 |
DOBELI, PROTEIN EXPR. PURIF., vol. 12, 1998, pages 404 - 414 |
ECKSTEIN ET AL., NUCL. ACIDS RES., vol. 13, 1985, pages 8764 - 8785 |
FENG, NATURE BIOTECHNOLOGY, vol. 15, 1997, pages 866 - 870 |
IWANE, BIOPHYS. BIOCHEM. RES. COMM., vol. 230, 1997, pages 76 - 80 |
JOHANN, J. VIROL., vol. 66, 1992, pages 1635 - 1640 |
JOHNSTON, CURR. BIOL., vol. 8, 1998, pages R171 - R174 |
KERN, BIOTECHNIQUES, vol. 23, 1997, pages 120 - 124 |
KROLL, DNA CELL. BIOL., vol. 12, 1993, pages 441 - 53 |
KUNKEL, PROC. NATL. ACAD. SCI., vol. 82, 1985, pages 488 - 492 |
LU, ANAL. CHEM., vol. 67, 1995, pages 83 - 87 |
NG, LANGMUIR, vol. 11, 1995, pages 4048 - 55 |
OKADA, GENE THER., vol. 3, 1996, pages 957 - 964 |
SCHUHMANN, ADV. MATER., vol. 3, 1991, pages 388 - 391 |
SCHUMMER, BIOTECHNIQUES, vol. 23, 1997, pages 1087 - 1092 |
SIGAL, ANAL. CHEM., vol. 68, 1996, pages 490 - 497 |
SOLINAS-TOLDO, GENES, CHROMOSOMES & CANCER, vol. 20, 1997, pages 399 - 407 |
WILLIAMS, BIOCHEMISTRY, vol. 34, 1995, pages 1787 - 1797 |
Cited By (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009523812A (ja) * | 2006-01-19 | 2009-06-25 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 融合へテロ二環式キナーゼ阻害剤 |
WO2008064255A3 (en) * | 2006-11-22 | 2008-08-14 | Plexxikon Inc | Compounds modulating c-fms and/or c-kit activity and uses therefor |
WO2008064265A3 (en) * | 2006-11-22 | 2008-11-13 | Plexxikon Inc | Compounds modulating c-fms and/or c-kit activity and uses therefor |
NO342175B1 (no) * | 2006-11-22 | 2018-04-09 | Plexxikon Inc | Kjemiske forbindelser, preparater omfattende slike forbindelser, slike forbindelser og preparater for behandling av sykdom samt sett omfattende slike forbindelser |
WO2008064265A2 (en) * | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
JP2018021055A (ja) * | 2006-11-22 | 2018-02-08 | プレキシコン インコーポレーテッドPlexxikon Inc. | C−fmsおよび/またはc−kit活性を調節する化合物およびその用途 |
WO2008080015A3 (en) * | 2006-12-21 | 2008-10-02 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
WO2008080001A3 (en) * | 2006-12-21 | 2009-01-08 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
WO2008080015A2 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2008080001A2 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9844539B2 (en) | 2007-07-17 | 2017-12-19 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10426760B2 (en) | 2007-07-17 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8173635B2 (en) | 2007-11-02 | 2012-05-08 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
US8367697B2 (en) | 2007-11-02 | 2013-02-05 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
WO2009111280A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
US8394795B2 (en) | 2008-02-29 | 2013-03-12 | Array Biopharma Inc. | Pyrazole [3, 4-B] pyridine Raf inhibitors |
US8338452B2 (en) | 2008-02-29 | 2012-12-25 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
WO2009143024A3 (en) * | 2008-05-19 | 2010-01-07 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009143024A2 (en) * | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8153641B2 (en) | 2008-05-19 | 2012-04-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9260437B2 (en) | 2008-05-19 | 2016-02-16 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009143018A3 (en) * | 2008-05-19 | 2010-04-15 | Plexxikon, Inc. | Pyrrolo [2, 3-d] pyrimidines as fm and kit kinase modulators |
US8912204B2 (en) | 2008-05-19 | 2014-12-16 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009143018A2 (en) * | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8110576B2 (en) | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
WO2009152087A1 (en) * | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor |
EP2313411A1 (en) * | 2008-06-10 | 2011-04-27 | Plexxikon, Inc. | 5h-pyrr0l0 [2,3-b]pyrazine derivatives for kinase modulation, and indications therefor |
JP2011522894A (ja) * | 2008-06-10 | 2011-08-04 | プレキシコン,インコーポレーテッド | キナーゼを調節する5h−ピロロ[2,3−b]ピラジン誘導体、およびその適応症 |
WO2010111527A1 (en) * | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
US9663517B2 (en) | 2009-04-03 | 2017-05-30 | Plexxikon Inc. | Compositions and uses thereof |
US8741920B2 (en) | 2009-08-03 | 2014-06-03 | Hoffmann-La Roche, Inc. | Process for the manufacture of pharmaceutically active compounds |
US8648086B2 (en) | 2009-08-24 | 2014-02-11 | Ascepion Pharmaceuticals, Inc. | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors |
WO2011025968A1 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase |
US9617267B2 (en) | 2009-11-18 | 2017-04-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9440969B2 (en) | 2009-12-23 | 2016-09-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8580803B2 (en) | 2009-12-30 | 2013-11-12 | Arqule, Inc. | Substituted pyrrolo-aminopyrimidine compounds |
US8901118B2 (en) | 2010-04-21 | 2014-12-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
AU2011242778B2 (en) * | 2010-04-21 | 2015-09-03 | Opna Immuno Oncology, SA | Compounds and methods for kinase modulation, and indications therefor |
KR101799126B1 (ko) | 2010-04-21 | 2017-11-17 | 플렉시콘 인코퍼레이티드 | 키나아제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
US9682981B2 (en) | 2010-04-21 | 2017-06-20 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
EP2560972A4 (en) * | 2010-04-21 | 2013-11-20 | Plexxikon Inc | COMPOSITIONS AND METHODS FOR MODULATING KINASES AND THEIR INDICATIONS |
EP2560972A2 (en) * | 2010-04-21 | 2013-02-27 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9624213B2 (en) | 2011-02-07 | 2017-04-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US11337976B2 (en) | 2011-02-07 | 2022-05-24 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9550768B2 (en) | 2011-05-17 | 2017-01-24 | Plexxikon Inc. | Kinase modulation and indications therefor |
EP3124472A1 (en) | 2011-12-31 | 2017-02-01 | BeiGene, Ltd. | Fused tricyclic compounds as raf kinase inhibitors |
US10123998B2 (en) | 2012-03-19 | 2018-11-13 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9730918B2 (en) | 2012-03-19 | 2017-08-15 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9695169B2 (en) | 2012-05-31 | 2017-07-04 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
EP3550031A1 (en) | 2012-07-24 | 2019-10-09 | Pharmacyclics, LLC | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
US10227357B2 (en) | 2012-09-06 | 2019-03-12 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9163021B2 (en) | 2012-10-04 | 2015-10-20 | Pfizer Limited | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors |
US10301280B2 (en) | 2012-12-21 | 2019-05-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9676748B2 (en) | 2012-12-21 | 2017-06-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9718847B2 (en) | 2013-03-15 | 2017-08-01 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9822109B2 (en) | 2013-03-15 | 2017-11-21 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9873700B2 (en) | 2013-05-30 | 2018-01-23 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
US10421761B2 (en) | 2013-05-30 | 2019-09-24 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
US9771369B2 (en) | 2014-03-04 | 2017-09-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9856259B2 (en) | 2014-09-15 | 2018-01-02 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US11274108B2 (en) | 2015-07-20 | 2022-03-15 | Genzyme Corporation | Colony stimulating factor-1 receptor (CSF-1R) inhibitors |
US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9975894B2 (en) | 2015-09-21 | 2018-05-22 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US10370374B2 (en) | 2015-09-21 | 2019-08-06 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US10899761B2 (en) | 2015-09-21 | 2021-01-26 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9771363B2 (en) | 2015-09-21 | 2017-09-26 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US10647716B2 (en) | 2015-09-21 | 2020-05-12 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US9938273B2 (en) | 2015-12-07 | 2018-04-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10933065B2 (en) | 2015-12-23 | 2021-03-02 | Arqule Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US11020400B2 (en) | 2015-12-23 | 2021-06-01 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US10245263B2 (en) | 2015-12-23 | 2019-04-02 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US10160747B2 (en) | 2016-03-16 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US11020398B2 (en) | 2016-08-24 | 2021-06-01 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
US10508085B2 (en) | 2016-09-22 | 2019-12-17 | Plexxikon Inc. | Compounds and methods for IDO and TDO modulation, and indications therefor |
US10703757B2 (en) | 2016-12-23 | 2020-07-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
US10577366B2 (en) | 2017-03-20 | 2020-03-03 | Plexxikon Inc. | Crystalline forms of a compound that inhibits bromodomain |
US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
US10941142B2 (en) | 2017-07-25 | 2021-03-09 | Plexxikon Inc. | Formulations of a compound modulating kinases |
US10961240B2 (en) | 2017-07-25 | 2021-03-30 | Plexxikon Inc. | Formulations of a compound modulating kinases |
US10435404B2 (en) | 2017-07-25 | 2019-10-08 | Plexxikon Inc. | Formulations of a compound modulating kinases |
US10717735B2 (en) | 2017-10-13 | 2020-07-21 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
US11103505B2 (en) | 2017-10-27 | 2021-08-31 | Plexxikon Inc. | Formulations of a compound modulating kinases |
US11858927B2 (en) | 2018-01-31 | 2024-01-02 | Heparegenix Gmbh | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
US11149011B2 (en) | 2018-03-20 | 2021-10-19 | Plexxikon Inc. | Compounds and methods for IDO and TDO modulation, and indications therefor |
US11731968B2 (en) | 2018-06-21 | 2023-08-22 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
US11912701B2 (en) | 2018-07-16 | 2024-02-27 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
WO2020079581A1 (en) | 2018-10-16 | 2020-04-23 | Novartis Ag | Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy |
WO2021144360A1 (en) | 2020-01-17 | 2021-07-22 | F. Hoffmann-La Roche Ag | Small molecule csf-1r inhibitors in therapeutic and cosmetic uses |
US11530216B2 (en) | 2020-12-23 | 2022-12-20 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors |
WO2022195551A1 (en) | 2021-03-18 | 2022-09-22 | Novartis Ag | Biomarkers for cancer and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2008545652A (ja) | 2008-12-18 |
CR9591A (es) | 2008-03-26 |
EP1885723A2 (en) | 2008-02-13 |
WO2007013896A3 (en) | 2007-05-31 |
US20070032519A1 (en) | 2007-02-08 |
MX2007014377A (es) | 2008-02-06 |
US20110166174A1 (en) | 2011-07-07 |
CA2608733A1 (en) | 2007-02-01 |
NO20075992L (no) | 2008-02-13 |
US7846941B2 (en) | 2010-12-07 |
BRPI0610066A2 (pt) | 2010-05-25 |
IL187344A0 (en) | 2008-04-13 |
AU2006272951A1 (en) | 2007-02-01 |
KR20080027775A (ko) | 2008-03-28 |
ECSP077985A (es) | 2008-01-23 |
NZ563444A (en) | 2011-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7846941B2 (en) | Compounds modulating c-kit and c-fms activity and uses therefor | |
US9487515B2 (en) | Compounds modulating c-fms and/or c-kit activity and uses therefor | |
US10426760B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
US10160747B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
US7872018B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
JP6113151B2 (ja) | キナーゼ調節およびその適応症 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680026005.5 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 187344 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4363/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007502546 Country of ref document: PH Ref document number: 563444 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2608733 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/014377 Country of ref document: MX Ref document number: 07121351 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2008512402 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006272951 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006813186 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2007-009591 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007142326 Country of ref document: RU Ref document number: 1020077029428 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006272951 Country of ref document: AU Date of ref document: 20060516 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0610066 Country of ref document: BR Kind code of ref document: A2 |